Sepantronium Bromide (YM155)
目录号:S1130 Purity: 99.45%
Sepantronium Bromide(YM155)是一种有效的survivin抑制药,通过抑制Survivin启动子活性而发挥作用,在HeLa-SURP-luc 和 CHO-SV40-luc细胞中IC50为0.54 nM;对SV40启动子活性抑制作用不显著,能够轻微抑制Survivin与XIAP相互作用。YM155 在乳腺癌细胞中可下调 survivin 和 XIAP、调节自噬并诱导自噬依赖的DNA损伤。Phase 2。
CAS: 781661-94-7
客户使用Selleck的Sepantronium Bromide (YM155)发表文献177篇
- Cancer Cell, 2022 S1535-6108(22)00312-9
- Blood, 2022 blood.2021014304
- Cell, 2019 36(2):179-193
- Cancer Cell, 2019 36(2):179-193
- Immunity, 2018 48(6):1183-1194
- J Hematol Oncol, 2015 0.36041666667
- J Hematol Oncol, 2014 7(1):62
- Cell Commun Signal, 2024 22(1):440
- iScience, 2024 27(7):110180
- Sci Rep, 2024 14(1):7604
- Adv Sci (Weinh), 2023 10(25):e2301753
- Cell Rep Med, 2023 4(12):101339
- Proc Natl Acad Sci U S A, 2023 120(4):e2218118120
- Cancer Gene Ther, 2023 30(4):608-621
- iScience, 2023 26(7):106976
- Nat Chem Biol, 2022 10.1038/s41589-022-00996-7
- Clin Exp Hypertens, 2022 44(5):470-479
- Cell Rep, 2022 38(9):110448
- Cell Commun Signal, 2022 20(1):99
- iScience, 2022 25(12):105526
- Mol Cancer Ther, 2022 molcanther.0619.2021
- Front Pharmacol, 2022 13:987398
- Cancers (Basel), 2022 15(1)208
- Cancers (Basel), 2022 14(19)4784
- Cancers (Basel), 2022 14(2)338
- Transl Oncol, 2022 26:101535
- J Biol Chem, 2022 S0021-9258(22)01285-6
- Biomedicines, 2022 10(3)638
- Mol Cell Biochem, 2022 10.1007/s11010-022-04383-7
- Curr Res Pharmacol Drug Discov, 2022 3:100076
- Cancer Treat Res Commun, 2022 32:100579
- Nat Commun, 2021 12(1):2877
- Nat Commun, 2021 12(1):2475
- J Clin Invest, 2021 131(10)146777
- Theranostics, 2021 11(20):9752-9771
- Proc Natl Acad Sci U S A, 2021 118(11)e2022779118
- Cancer Lett, 2021 517:66-77
- Cell Commun Signal, 2021 19(1):97
- Life Sci, 2021 287:120119
- Food Funct, 2021 10.1039/d0fo02243h
- Front Cell Dev Biol, 2021 9:671461
- Biochim Biophys Acta Mol Cell Res, 2021 1869(2):119174
- Onco Targets Ther, 2021 14:5493-5505
- J Cancer Res Clin Oncol, 2021 10.1007/s00432-021-03871-5
- Int J Ophthalmol, 2021 14(4):489-496
- Chin J Dent Res, 2021 24(1):21-31
- Frontiers in-Molecular Biosciences, 2020- Volume 7
- Nat Commun, 2020 11(1):5722
- Cancer Res, 2020 80(17):3480-3491
- Eur J Cancer, 2020 126:93-103
- Elife, 2020 26;9:e55487
- Mol Cancer Ther, 2020 4;molcanther.1166.2020
- Mol Cancer Res, 2020 10.1158/1541-7786.MCR-19-0669
- Cancers (Basel), 2020 2;12(3) pii: E577
- Front Mol Biosci, 2020 7:566291
- World J Gastroenterol, 2020 26(32):4786-4801
- Cell Cycle, 2020 1-10
- BMC Cancer, 2020 20(1):617
- PLoS One, 2020 13;15(1):e0226917
- Oncol Lett, 2020 20(4):72
- Head Neck, 2020 42(5):913-923
- Mol Cancer Res, 2019 17(10):1985-1998
- Lab Invest, 2019 99(5):612-624
- Ann Transl Med, 2019 7(14):316
- Sci Rep, 2019 9(1):1897
- Sci Rep, 2019 9(1):14375
- Sci Rep, 2019 9(1):11541
- J Proteome Res, 2019 18(5):2012-2020
- Pigment Cell Melanoma Res, 2019 10.1111/pcmr.12841
- PLoS One, 2019 14(8):e0220860
- Prostate, 2019 79(4):352-362
- Mol Syst Biol, 2018 14(8):e8238
- Biomed Pharmacother, 2018 107:139-145
- J Transl Med, 2018 16(1):79
- Cell Death Discov, 2018 4:107
- Biochim Biophys Acta Mol Basis Dis, 2018 1864(12):3786-3798
- Int J Mol Sci, 2018 19(2)
- Oncotarget, 2018 9(71):33589-33600
- Oncotarget, 2018 9(49):29180-29192
- Chem Res Toxicol, 2018 31(7):612-618
- Onco Targets Ther, 2018
- Toxicol Lett, 2018 292:55-62
- Oncol Lett, 2018 15(3):3779-3789
- Nat Commun, 2017 8(1):435
- Small, 2017 13(27)
- Biochim Biophys Acta Mol Basis Dis, 2017 1863(3):663-673
- Stem Cells Transl Med, 2017 6(2):382-393
- Mol Cancer Ther, 2017 16(10):2178-2190
- Oncotarget, 2017 8(34):57047-57057
- Oncotarget, 2017
- Transl Oncol, 2017 10(4):546-554
- Sci Rep, 2017
- Sci Rep, 2017 7:40723
- Cell Physiol Biochem, 2017 44(1):293-302
- Mol Cell Biochem, 2017 429(1-2):91-102
- Med Sci Monit, 2017 23:1963-1972
- SLAS Discov, 2017 22(5):507-515
- Oncol Lett, 2017 14(3):3832-3838
- Bioorg Med Chem Lett, 2017 27(17):4001-4006
- Anticancer Drugs, 2017 28(2):142-152
- Anticancer Res, 2017 37(1):75-80
- J Chemother, 2017 29(3):179-188
- Tumour Biol, 2017 39(6):1010428317706213
- Cell Death Dis, 2016 7(10):e2410
- Oncogenesis, 2016 10.1038/oncsis.2016.33
- Oncotarget, 2016 7(24):37030-37042
- Oncotarget, 2016 7(38):61520-61532
- Int J Oncol, 2016 48(5):1847-54
- Mol Pharm, 2016 13(11):3724-3735
- Gynecol Oncol, 2016 141(3):564-569
- PLoS Genet, 2016 12(9):e1006279
- Cell Physiol Biochem, 2016 38(6):2426-37
- PLoS One, 2016 11(4):e0153011
- Mol Med Rep, 2016 13(4):3415-22
- Eur Rev Med Pharmacol Sci, 2016 20(7):1251-7
- Biochem Biophys Res Commun, 2016 471(2):309-14
- Photochem Photobiol Sci, 2016 15(6):812-21
- Cancer Invest, 2016 34(8):401-7
- Clin Exp Hypertens, 2015 10.3109/10641963.2014.987390
- Cancer Lett, 2015 366(1):44-51
- Cancer Lett, 2015 366(2):160-72
- Cell Death Dis, 2015
- Sci Signal, 2015 8(389):ra80
- Mol Oncol, 2015 9(2):527-43
- Mol Cancer Ther, 2015
- Oncotarget, 2015 6(30):28895-910
- Oncotarget, 2015 6(9):7123-35
- Oncotarget, 2015 6(15):13119-32
- Oncotarget, 2015 6(15):13476-86
- Int J Oncol, 2015 46(2):841-8
- Oncol Rep, 2015 34(1):407-14
- Oncol Rep, 2015 34(2):1074-80
- Mol Endocrinol, 2015 29(12):1694-707
- Biomed Res Int, 2015 2015:630397
- Oncol Lett, 2015 10(3):1627-1631
- J Orthop Res, 2015 10.1002/jor.22819
- Leuk Res, 2015 39(12):1473-9
- Cell Biochem Biophys, 2015 71(2):587-93
- Int J Clin Exp Med, 2015 8(10):18032-40
- Nat Chem Biol, 2014 10(9):768-73
- Cell Death Dis, 2014 5:e1543
- J Dent Res, 2014 10.1177/0022034514553815
- Breast Cancer Res, 2014 16(3):R55
- Br J Pharmacol, 2014 172(1):214-34
- Apoptosis, 2014 19(4):748-58
- Int J Cancer, 2014 10.1002/ijc.28993
- Biochem Pharmacol, 2014 89(1):31-42
- Oncotarget, 2014 5(21):10237-50
- World J Gastroentero, 2014 11644
- World J Gastroenterol, 2014 20(45):17049-64
- Oncol Rep, 2014 31(2):771-80
- PLoS One, 2014 9(12):e114051
- J Cancer Res Clin Oncol, 2014 140(10):1705-13
- J Pharm Biomed Anal, 2014 92:144-8
- J Oral Pathol Med, 2014 10.1111/jop.12248
- J Oral Pathol Med, 2014 10.1111/jop.12299
- Leuk Lymphoma, 2014 5:1-12
- Anticancer Res, 2014 34(10):5287-94
- Clin Cancer Res, 2013 19(20):5591-601
- Cancer Res, 2013 73(3):1190-200
- Cell Death Dis, 2013 4:e471
- Mol Oncol, 2013 8(3):469-82
- Int J Cancer, 2013 133(10):2341-50
- Int J Biochem Cell Biol, 2013 45(9):2036-44
- PLoS One, 2013 8(12):e80703
- Pediatr Blood Cancer, 2013 60(1):35-40
- Biochem Biophys Res Commun, 2013 435(1):52-7
- Leukemia, 2012 26(4):623-32
- Proc Natl Acad Sci USA, 2012 109(2):600-5
- Mol Cancer Ther, 2012 11(9):1988-98
- Int J Biochem Cell Biol, 2012 44(1):158-69
- BMC Cancer, 2012 12:619
- Pediatr Neonatol, 2012 53(3):199-204
- Anticancer Res, 2012 32(5):1681-8
- Adv Biosci Biotechnol, 2012 3(6A):657-664
- Basic Res Cardiol, 2011 106(6):1207-20
- PLoS One, 2011 6(8):e21980
化学信息&溶解度
分子量 | 443.29 |
分子式 | C20H19BrN4O3 |
CAS号 | 781661-94-7 |
Smiles | CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-] |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
Water : 89 mg/mL DMSO : 55 mg/mL ( 124.07 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 6 mg/mL DMSO : 89 mg/mL ( 200.77 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 89 mg/mL Ethanol : 11 mg/mL Water : 89 mg/mL DMSO : 60 mg/mL ( 135.35 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 9 mg/mL |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
Saline
浓度:30mg/ml
(67.68mM)
操作示例:以 1 mL 工作液为例,取30mg该产品加到1ml生理盐水(0.9% NaCL溶液)中,混合均匀使其澄清,请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。